Author

Bao V. Nguyen

University of Massachusetts AmherstORCID 0000-0002-4693-3098Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Approach:statistical model· 1 Assay:structural biology· 1

Frequent Co-Authors

Margaret M. StrattoniD· 2 shared Ana P. Torres‐OcampoiD· 1 shared Anderly C. ChüehiD· 1 shared Andrew M. EllisdoniD· 1 shared Can ÖzdeniD· 1 shared Changyuan HuiD· 1 shared Charles Bayly-JonesiD· 1 shared Daniel Flaherty· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Margaret M. StrattonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryNature CommunicationsPeer-reviewedSep 26, 2025

A domain-swapped CaMKII conformation facilitates linker-mediated allosteric regulation

Bao V. Nguyen, Can Özden, Kairong Dong…·Margaret M. Stratton

This study identifies a domain-swapped conformation in CaMKII that enables linker-mediated allosteric regulation, demonstrated through structural, computational, and live-cell analyses.

5 citations

structural biologyexperimental assay

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedFeb 21, 2025

Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer

Xue Yang, Xiuquan Ma, Tianyue Zhao…·Roger J. Daly

This study identifies a novel feed-forward signalling axis between PEAK1 and CAMK2 in TNBC, showing that targeting CAMK2 can inhibit PEAK1-driven oncogenic processes.

10 citations

humanproteomics

𝕏 PostBluesky